CONTROLLED VAGAL BLOCKAGE THERAPY

• US 20110034968A1
• Filed: 10/20/2010
• Published: 02/10/2011
• Est. Priority Date: 02/03/2003
• Status: Active Grant

• Current Assignee: ReShape LifeSciences, Inc.
• Original Assignee: EnteroMedics, Inc. (ReShape LifeSciences, Inc.)
• Inventors: Knudson, Mark B., Wilson, Richard R., Tweden, Katherine S., Conrad, Timothy R.
• Granted Patent: US 8,046,085 B2
• Time in Patent Office: Days
• US Class Current: 607/40
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61N 1/321 Electromedical belts
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36053 adapted for vagal stimulation A61N1/36114 takes precedence
• CPC Class Codes: A61N 1/36071 Pain
• CPC Class Codes: A61N 1/36085 Eating disorders or obesity
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/36178 Burst or pulse train parameters

Abstract

A method for treating at least one of a plurality of disorders characterized at least in part by vagal activity includes positioning an electrode around a body organ innervated by the vagus. An electrical signal is applied to the electrode to modulate vagal activity. The electrical signal is applied at a frequency selected for the signal to create a neural conduction block to the vagus with the neural conduction block selected to at least partially block nerve impulses on the vagus. The application of the electrical signal is discontinued. The application of the signal and the discontinuing of the signal are repeated with durations of the discontinuing and the application selected to treat the disorder.

Claims

1. A method for treating at least one of a plurality of disorders of a patient where the disorders are characterized at least in part by vagal activity innervating at least one of a plurality of alimentary tract organs of said patient at an innervation site, said method comprising:

positioning a neurostimulator carrier around a body organ of said patient where said organ is innervated by at least a vagal trunk or branch and with an electrode disposed on said carrier and positioned at said vagal trunk or branch;

applying an electrical signal to said electrode to modulate vagal activity by an amount selected to treat said disorder;

said electrical signal is applied at a frequency selected for said signal to create a neural conduction block to said trunk or branch at a blocking site with said neural conduction block selected to at least partially block nerve impulses on said trunk at said blocking site;

discontinuing said application of said electrical signal;

repeating said application of said signal and said discontinuing of said signal with durations of said discontinuing and said application selected to treat said disorder.

2. A method according to claim 1 wherein application of said neural conduction block is variable by a controller to alter a characteristic of said block.

3. A method according to claim 1 wherein said at least one of a plurality of disorders is obesity.

4. A method according to claim 3 wherein said neural conduction block is regulated to heighten a sensation of satiety of said patient.

5. A method according to claim 3 wherein said neural conduction block is regulated to reduce a production of pancreatic enzymes of said patient.

6. A method according to claim 1 wherein said organ is a stomach of said patient.

7. A method according to claim 1 wherein said organ is an esophagus of said patient.

8. A method according to claim 1 wherein said duration of said discontinuing of said signal is selected to avoid excessive fecal fat in a stool of said patient.

9. A method according to claim 1 further comprising monitoring vagal activity of said patient and said duration of said discontinuing is selected to permit said vagal activity to at least partial restore before re-applying said signal.

10. A method according to claim 9 wherein said monitoring includes monitoring a discomfort of said patient.

11. A method according to claim 9 wherein said monitoring includes monitoring a fecal fat content of said patient.

12. A method according to claim 9 wherein said monitoring includes electrically monitoring a neural activity of said patient.